A recent Intensive Care digest,
as sent to subscribers

Study Type: Retrospective observational study (doubly robust differences-in-differences analysis)

Key Question: Did a city-wide public housing mold remediation programme ('Mold Busters') reduce asthma-related ED visits among NYCHA residents?

Key Findings:

• 'Mold Busters' was associated with an average annual reduction of 7.2 asthma-related ED visits per 1,000 residents (95% CI: -9.6, -4.8), equating to ~2,200 fewer visits annually by 2022–2023 (19% lower than expected).
• Buildings with the greatest reduction in mold reports saw visit-rate reductions up to 12.0 per 1,000 residents (95% CI: -16.9, -7.0).
• Effects were stronger in adults than children and more pronounced in winter/spring; mold reports still rose after extreme precipitation.

Clinical Relevance: Highlights housing-based environmental intervention as a scalable, upstream strategy to reduce asthma exacerbations and associated ED burden—relevant to UK critical care/respiratory teams managing asthma admissions linked to damp/mold housing, particularly in deprived populations.

Limitations: Observational design precludes definitive causal inference despite robust statistical adjustment, and unmeasured confounding (e.g., other concurrent housing improvements) cannot be excluded.

Study Type: Narrative review/commentary on methodology in nutrition research.

Key Question: Why do observational studies suggest higher protein intake improves survival in critical illness, while recent RCTs (EFFORT Protein, PRECISe, TARGET Protein) show no benefit?

Key Findings:

• Older observational studies (2009–2017) consistently associated higher protein intake with lower mortality, but this contradicts three major RCTs (2023–2025) showing no benefit.
• Authors identify multiple specific biases likely responsible, including immortal time bias, confounding by indication, time-axis violations, competing-risk bias, collider bias, and inappropriate handling of missing data/wash-in periods.
• They recommend target-trial emulation designs and advanced statistical methods (time-varying analysis, nonlinear modelling, lag-time adjustment) to improve future observational nutrition research.

Clinical Relevance: UK intensivists should be cautious interpreting observational nutrition data when setting protein targets, and should prioritise RCT evidence (e.g., EFFORT Protein) over historical association-based guidance in local protocols.

Limitations: As a methodological commentary rather than original data analysis, it offers no new empirical evidence, only theoretical explanations for observed discrepancies.

Study Type: Retrospective bi-centre cohort study using target trial emulation with propensity-score overlap weighting.

Key Question: Does routine mechanical LV unloading (Impella or IABP) improve 60-day survival in patients on VA-ECMO for refractory cardiogenic shock?

Key Findings:

• Among 264 patients, 47.8% received LV unloading (78 IABP, 48 Impella) versus VA-ECMO alone; no significant 60-day mortality difference (weighted risk difference 1.4%, 95% CI -11.8% to 14.6%, p=0.84).
• No significant difference in ECMO weaning rates between groups.
• Device-related complications were more frequent with LV unloading.

Clinical Relevance: These findings challenge routine adoption of adjunctive LV unloading in UK ECMO centres, supporting a more selective, phenotype-driven approach rather than blanket application given added complication risk without proven survival benefit.

Limitations: Retrospective, non-randomised design with potential residual confounding despite propensity-score weighting, limiting causal inference.

Study Type: International multicentre three-arm RCT

Key Question: Does a single ICU-specific virtual reality (ICU-VR) video, delivered early or late post-ICU, improve PTSD, anxiety, depression, or HRQoL at 6 months compared with standard care?

Key Findings:

• No difference in PTSD severity (IES-R) at 6 months: early vs control β=0.32 (95% CI -3.38 to 4.02, p=0.87); late vs control β=-0.82 (95% CI -4.62 to 2.97, p=0.67).
• No significant between-group differences in anxiety, depression, or HRQoL (all p>0.05).
• Patients rated the intervention highly for satisfaction and understanding of their ICU experience (median 8/10), despite no measurable psychological benefit.

Clinical Relevance: UK critical care follow-up services considering single-session ICU-VR as a PICS mitigation tool should note it does not reduce psychological morbidity, informing resource allocation in ICU aftercare pathways.

Limitations: Findings apply only to a single, standardised ICU-VR session and cannot be extrapolated to multi-session, personalised, or therapist-guided VR interventions.

Study Type: Descriptive comparative analysis of three open-access ICU databases.

Key Question: Are MIMIC-IV, eICU-CRD, and AmsterdamUMCdb sufficiently complete and standardised to support reliable AI-based sepsis research?

Key Findings:

• MIMIC-IV showed major missingness (medication route 49%, dose 58%, microbiology quantity 99.9%) and diagnosis redundancy (17,557 unique strings, 174 near-duplicates).
• eICU-CRD had 1.9% admissions missing diagnosis and mortality discordance (ICU vs hospital) in 7,319 stays.
• AmsterdamUMCdb had fewer structural errors but 61.4% of admissions lacked diagnosis coding, plus mixed English-Dutch terminology; all three databases lacked reliable sepsis onset timestamps.

Clinical Relevance: UK intensivists developing or appraising AI sepsis tools trained on these widely-used public datasets should be aware that underlying data quality issues may compromise model validity, reproducibility, and generalisability to NHS populations.

Limitations: The study is descriptive and database-specific, without external validation against a gold-standard clinical dataset.

Study Type: Narrative literature review

Key Question: How does the human (particularly gastrointestinal) microbiome influence pathophysiology, treatment response, and outcomes in critically ill patients?

Key Findings:

• Distinct microbiomes exist across body sites (eyes, skin, oropharynx, lung, bladder, gut), with the gastrointestinal microbiome most implicated in critical illness recovery or deterioration.
• ICU disease processes and standard therapeutics (e.g., antibiotics, sedation, nutrition changes) commonly disrupt microbial balance ("pathobiome" induction), which may worsen organ dysfunction.
• No quantitative outcome data are presented; the review is conceptual/synthesis-based rather than reporting effect sizes.

Clinical Relevance: Understanding microbiome disruption and restoration strategies may inform future ICU practices (e.g., antibiotic stewardship, nutrition, probiotic/prebiotic use) aimed at improving outcomes—an emerging consideration for UK critical care teams as microbiome-targeted therapies develop.

Limitations: As a narrative review without systematic methodology or meta-analysis, conclusions are descriptive and not derived from pooled quantitative evidence.

Study Type: Narrative review

Key Question: How should ARDS in trauma patients be understood pathophysiologically and managed clinically?

Key Findings:

• ARDS in trauma follows a "multi-hit" model: initial injury, dysregulated inflammation, and secondary insults (transfusion, infection, fat embolism) drive alveolar-capillary damage.
• Risk stratification relies on clinical severity scores combined with multimodal thoracic imaging (chest X-ray, lung ultrasound, CT).
• Management centres on lung-protective ventilation, selective non-invasive support, analgesia, haemodynamic optimisation, and timely surgery to limit progression; special considerations apply in traumatic brain injury and hypothermia due to brain-lung interactions.

Clinical Relevance: Provides UK intensivists a structured, physiology-based framework for early recognition and multidisciplinary management of trauma-related ARDS, relevant to major trauma centre pathways and critical care ventilation protocols.

Limitations: As a narrative review, it synthesises existing evidence without new primary data or systematic methodology, limiting quantitative certainty.

Study Type: Narrative state-of-the-art review

Key Question: What is the current evidence for using ß-blockers to modulate the adrenergic response in critically ill patients, and in which contexts is this beneficial or harmful?

Key Findings:

• Established benefit for ß-blockade exists in specific conditions: acute MI, tachyarrhythmias, hypertensive emergencies, thyroid storm, and variceal bleed prevention.
• Evidence is limited/conflicting in septic shock, traumatic brain injury, acute heart failure, and burns, with risks of impaired compensatory responses, reduced cardiac output, hypotension, and organ hypoperfusion.
• Efficacy/safety depend on drug choice, dose, timing (continuation vs. de novo initiation vs. withdrawal), patient phenotype, and haemodynamic reserve.

Clinical Relevance: UK intensivists frequently manage chronic ß-blocker therapy and consider adrenergic modulation in shock states; this review highlights the need for individualised, physiology-guided decision-making rather than blanket protocols.

Limitations: As a narrative review, it synthesises heterogeneous and largely non-randomised evidence without systematic methodology, limiting the strength of conclusions.